One Key Merck Product Absolutely Demolished Forecasts

The Merck Product That Absolutely Demolished Wall Street's Forecasts

Licensing

06:30 AM ET 08/04/2026

Merck's (MRK) new injectable version of Keytruda walloped sales expectations Tuesday, packing a $200 million-plus punch vs. Wall Street's forecasts. Keytruda, a cancer drug, is Merck's biggest product — responsible for roughly half of total sales. It's typically given via an intravenous infusion. The new under-the-skin shot, Keytruda Qlex, brought in $463 million in second-quarter sales, demolishing projections for $283…